-
Thematic Analysis
NewTelecom Infrastructure Sector Scorecard, Q1 2024 Update – Thematic Intelligence
The thematic screen of GlobalData’s telecom infrastructure sector scorecard is led by global vendors that score well in the themes related to cloud computing (e.g., programmable infrastructure, edge computing, private networks), 5G, and artificial intelligence (AI). The leaders include US network vendor Cisco, European radio access network (RAN) specialists Nokia and Ericsson, and innovative new entrants such as Mavenir and Rakuten, which is reaping the benefits of acquiring Open RAN vendor Altiostar.
-
Product Insights
NewLikelihood of Approval Analysis for Neisseriaceae Infections
Overview How likely is it that the drugs in Neisseriaceae Infections will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Neisseriaceae Infections Overview The Neisseriaceae family encompasses a group of bacteria, including...
-
Thematic Analysis
NewGeneric Drugs – Physician Perspective – Thematic Intelligence
Reasons to buy the ‘Generic Drugs – Physician Perspective’ thematic intelligence report: Assess healthcare professionals’ attitudes towards generic drugs prescription. Better understand the barriers to the production and uptake of generic medicines. Capture physicians’ opinions on generics substitution. Better understand patients’ preferences. Assess past and future generics uptake. Gain a better understanding of cost consideration when prescribing drugs. Explore the differences across markets. How is our ‘Generic Drugs – Physician Perspective’ report unique from other reports in the market? This...
-
Sector Analysis
NewUnited Kingdom (UK) Easter Intentions and Consumer Spending Preferences, 2024 Update
The GlobalData Retail Easter intentions 2024 report forms part of the Retail Occasions series, and offers a comprehensive overview of the retail occasion of Easter, analysing consumers intentions for spending, gifting and celebrating.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ORM-5029 in Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ORM-5029 in Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ORM-5029 in Ovarian Cancer Drug Details: ORM-5029 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ORM-5029 in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ORM-5029 in Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ORM-5029 in Colorectal Cancer Drug Details: ORM-5029 is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ORM-5029 in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ORM-5029 in Gastric Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ORM-5029 in Gastric Cancer Drug Details: ORM-5029 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ORM-5029 in Bladder Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ORM-5029 in Bladder Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ORM-5029 in Bladder Cancer Drug Details: ORM-5029 is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ORM-5029 in Bile Duct Cancer (Cholangiocarcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ORM-5029 in Bile Duct Cancer (Cholangiocarcinoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ORM-5029 in Bile Duct Cancer (Cholangiocarcinoma) Drug Details: ORM-5029 is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ORM-5029 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ORM-5029 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ORM-5029 in Non-Small Cell Lung Cancer Drug Details: ORM-5029 is...